Attached is a link to a new analysis that I have done on Aurora Kinase inhibitors. The Aurora kinase is one of the hottest kinase targets around at the moment, inhibitors having the potential as anti-cancer drugs. Most advanced in this area is Vertex with it’s drug VX-680 in Phase II trials for colorectal cancer. Hot on Vertex’s heels are Nerviano, Astex and AstraZeneca, all with promising compounds in clinical development.
In terms of intellectual property Vertex leads the pack with AstraZeneca and Cyclacel also having impressing aurora kinase inhibitor portfolios. It’s important to note however that there are many potential patents out there that probably do not mention aurora kinase specificity – so judgements based on the number of patents listed needed to be made with caution.
Information for this table has been found by searching the internet; WIPO and USPTO patent sites; and PubMed. Please do feel free to let me know if you find this table usefuel, have any further information to add or have any other suggestions about how the information could be displayed.
